M. Escoffre-barbe

发表

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

J. Bourhis, H. Dombret, P. Chevallier, 2015, Blood.

Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study.

P. Rousselot, F. Nicolini, L. Roy, 2018, Experimental hematology.

Switches of tyrosine‐kinase inhibitors in chronic phase of chronic myeloid leukemia in real life

T. Fest, P. Moreau, O. Allangba, 2018, American journal of hematology.

The use of recombinant factor VIIa (NovoSeven) in a patient with a factor XI deficiency and a circulating anticoagulant.

J. Abgrall, M. Vicariot, C. Le Niger, 2001, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.

J. Cayuela, P. Cony-Makhoul, M. Tulliez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 2 study of L‐asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL‐SA2‐2008 study

H. Dombret, S. Leprêtre, P. Chevallier, 2015, American journal of hematology.

Addition of Androgens Improves Survival in Elderly Patients With Acute Myeloid Leukemia: A GOELAMS Study.

M. Béné, C. Récher, F. Bauduer, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

H. Dombret, S. Chevret, P. Chevallier, 2016, The New England journal of medicine.

Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.

P. Sonneveld, M. Mohty, M. Béné, 2021, The Lancet. Oncology.

Upfront Carfilzomib, Lenalidomide, Dexamethasone with Transplant in Multiple Myeloma Patients, the IFM KRd final results.

P. Moreau, X. Leleu, C. Touzeau, 2021, Blood.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

P. Sonneveld, M. Béné, M. Vekemans, 2019, The Lancet.

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.

B. Pégourié, M. Mohty, P. Moreau, 2018, Blood.

Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients

P. Cony-Makhoul, T. Henni, P. Rousselot, 2019, Clinical Cancer Research.

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.

M. Tulliez, G. Guillerm, P. Rousselot, 2017, Blood.

Reply to J. Richter et al.

J. Cayuela, P. Cony-Makhoul, M. Tulliez, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Longer treatment duration and history of osteoarticular symptoms predispose to tyrosine kinase inhibitor withdrawal syndrome

P. Cony-Makhoul, C. Lambert, P. Rousselot, 2019, British journal of haematology.

Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort

P. Cony-Makhoul, P. Rousselot, F. Mahon, 2015 .

Loss Of Major Molecular Response As a Trigger For Restarting Tyrosine Kinase Inhibitor Therapy In CP-CML Patients Who Have Stopped Imatinib After Durable Undetectable Minimal Residual Disease

J. Cayuela, P. Cony-Makhoul, M. Tulliez, 2013 .

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

B. Pégourié, O. Decaux, P. Moreau, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

High Response Rates to Pomalidomide and Dexamethasone in Patients with Refractory Myeloma, Final Analysis of IFM 2009-02

B. Pégourié, O. Decaux, P. Moreau, 2011 .

Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study.

Jean-Michel Nguyen, Caroline Bodet-Milin, Kenneth Anderson, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High tumor burden before blinatumomab has a negative impact on the outcome of adult patients with B-cell precursor acute lymphoblastic leukemia. A real-world study by the GRAALL

E. Clappier, H. Dombret, P. Chevallier, 2022, Haematologica.

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

M. Beksac, M. Dimopoulos, B. Pégourié, 2019, The Lancet.

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results.

B. Pégourié, O. Decaux, P. Moreau, 2015, Blood.

Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009-02.

B. Pégourié, O. Decaux, P. Moreau, 2013, Blood.

S. Leyvraz, Sung-Soo Yoon, C. Langer, 2014 .

Pomalidomide Plus Low-Dose Dexamethasone In Relapsed Or Refractory Multiple Myeloma (RRMM) With Deletion (del)17p and/Or Translocation t(4;14)

B. Pégourié, O. Decaux, P. Moreau, 2013 .

High-dose therapy followed by autologous purged stem-cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by GOELAMS.

R. Gressin, E. Deconinck, P. Cornillet‐Lefèbvre, 2005, Blood.

C. Récher, E. Jourdan, A. Pigneux, 2011, International Journal of Clinical Pharmacy.

Pediatric-inspired intensified therapy of adult T-ALL reveals the favorable outcome of NOTCH1/FBXW7 mutations, but not of low ERG/BAALC expression: a GRAALL study.

H. Dombret, E. Macintyre, S. Leprêtre, 2011, Blood.

Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia

Marc C. Jacob, M. Boubaya, J. Rossi, 2020, Leukemia.

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia.

J. Cayuela, H. Dombret, S. Leprêtre, 2015, Blood.

A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study

Philippe Rousselot, H. Dombret, A. Delannoy, 2011, Haematologica.

Addition of Rituximab Improves the Outcome of Adult Patients with CD20-Positive, Ph-Negative, B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL): Results of the Randomized Graall-R 2005 Study

H. Dombret, S. Chevret, P. Chevallier, 2015 .

The Omission of High-Dose Cytarabine during Consolidation Therapy of Ph-Positive ALL Patients Treated with Nilotinib and Low-Intensity Chemotherapy Results in an Increased Risk of Relapses Despite Non-Inferior Levels of Late BCR-ABL1 MRD Response. First Results of the Randomized Graaph-2014 Study

F. Pasquier, E. Clappier, J. Cayuela, 2021, Blood.

Frontline Consolidation with Blinatumomab for High-Risk Philadelphia-Negative Acute Lymphoblastic Adult Patients. Early Results from the Graall-2014-QUEST Phase 2

F. Pasquier, E. Clappier, H. Dombret, 2021, Blood.

Nilotinib (Tasigna®) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1-Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

J. Cayuela, H. Dombret, K. Spiekermann, 2018, Blood.

The p16(INK4A)/pRb pathway and telomerase activity define a subgroup of Ph+ adult Acute Lymphoblastic Leukemia associated with inferior outcome.

G. Salles, H. Dombret, M. Béné, 2015, Leukemia research.

BCR‐ABL1 molecular remission after 90Y‐epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B‐ALL: proof of principle

P. Chevallier, C. Bodet-Milin, F. Kraeber-Bodéré, 2013, European journal of haematology.

Outcome of patients with T-cell lymphoblastic leukemia or lymphoma: The GRAALL experience

H. Dombret, E. Macintyre, S. Leprêtre, 2007 .

S. Leyvraz, Sung-Soo Yoon, C. Langer, 2015, Haematologica.

Long-term results of a randomized phase 3 trial comparing idarubicin and daunorubicin in younger patients with acute myeloid leukaemia

M. Béné, C. Récher, N. Ifrah, 2014, Leukemia.

Addition of lomustine to idarubicin and cytarabine improves the outcome of elderly patients with de novo acute myeloid leukemia: a report from the GOELAMS.

M. Béné, J. Reiffers, C. Récher, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Multicenter Randomized Comparison of Maintenance Treatment with Androgens in Elderly Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the Goelams-2002 Study.

M. Béné, C. Récher, F. Bauduer, 2006 .

Hevylite® to Monitor Response to Therapy in Multiple Myeloma

B. Pégourié, O. Decaux, P. Moreau, 2014 .

Improved Outcome with Androgens as Maintenance Treatment in Elderly Patients with Acute Myeloid Leukemia after ICL Regimen as Induction Therapy: Results of the GOELAMS SA-2002 Multicenter Phase III Randomized Open Trial

M. Béné, C. Récher, F. Bauduer, 2008 .

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

H. Dombret, A. Stamatoullas, P. Greenberg, 2008, Blood.

A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma: The GOELAMS LCP 99 trial

P. Ingrand, P. Colombat, P. Solal-Céligny, 2014, American journal of hematology.

(90)Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study.

P. Chevallier, M. Béné, X. Thomas, 2015, The Lancet. Haematology.

First Results of the GRAAPH-2005 Study in younger Adult Patients with De Novo Philadelphia Positive Acute Lymphoblastic Leukemia

J. Cayuela, H. Dombret, S. Leprêtre, 2008 .

Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial.

H. Dombret, E. Macintyre, S. Leprêtre, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of Central Nervous System Involvement in Adult Patients with Acute Lymphoblastic Leukemia Treated in a Pediatrics-Inspired Protocol - a Graall Study

F. Pasquier, H. Dombret, S. Leprêtre, 2021, Blood.

Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma: an IFM randomized phase 3 study.

M. Vekemans, P. Moreau, H. Avet-Loiseau, 2022, Blood.

[Management of the cardiovascular disease risk during nilotinib treatment in chronic myeloid leukemia: 2015 recommendations from the France Intergroupe des Leucémies Myéloïdes Chroniques].

P. Cony-Makhoul, E. Messas, M. Tulliez, 2016, Bulletin du cancer.

Treatment of patients with advanced or bulky Hodgkin disease with a 12‐week doxorubicin, bleomycin, vinblastine, and dacarbazine‐like chemotherapy regimen followed by extended‐field, full‐dose radiotherapy

S. Oudard, J. Brière, J. Andrieu, 2002, Cancer.

Personalized daily doses of imatinib by therapeutic drug monitoring increase the rates of molecular responses in patients with Chronic Myeloid Leukemia - Final results of the randomized Optim imatinib study: Co-028

J. Cayuela, P. Cony-Makhoul, P. Rousselot, 2015 .

The Upper Age Limit for a Pediatric-Inspired Therapy in Younger Adults with Ph-Negative Acute Lymphoblastic Leukemia (ALL)? Analysis of the Graall-2005 Study

H. Dombret, E. Macintyre, S. Leprêtre, 2016 .

Nilotinib (Tasigna®) and chemotherapy for first-line treatment in elderly patients with De Novo Philadelphia chromosome/BCR-ABL1 positive acute Lymphoblastic Leukemia (ALL): A trial of the European Working Group for Adult ALL (EWALL-PH-02)

N. Schmitz, J. Cayuela, H. Dombret, 2014 .

Is Less Chemotherapy Detrimental in Adults with Philadelphia Chromosome (Ph)-Positive Acute Lymphoblastic Leukemia (ALL) Treated with High-Dose Imatinib? Results of the Prospective Randomized Graaph-2005 Study

J. Cayuela, H. Dombret, S. Leprêtre, 2012 .

A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia.

H. Dombret, H. Kantarjian, J. Cortes, 2016, Clinical lymphoma, myeloma & leukemia.

Results of the AFR07 Prospective Study in De Novo Philadelphia Positive ALL Patients Aged over 55 Years: Efficacy and Safety of a Glivec® Based Induction Followed by Maintenance Therapy with Glivec® and Pegasys®.

J. Cayuela, H. Dombret, C. Récher, 2007 .

Phase I/II Study of Escalating Doses of Idarubicin in Combination with Methotrexate, Vindesine and Prednisolone in Patients with Primary Central Nervous System Lymphoma: Results of the GOELAMS LCP99 Multicenter Trial.

P. Ingrand, P. Colombat, P. Solal-Céligny, 2009 .

The TKI-Free Duration after a First Discontinuation Attempt That Failed in CP CML Patients Is a Predictive Factor of TKI-Free Remission after a Second Attempt.

P. Rousselot, F. Mahon, F. Nicolini, 2019, Blood.

Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients

J. Cayuela, P. Cony-Makhoul, L. Busque, 2021, British journal of haematology.

Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l‐asparaginase: The GRAALL experience

H. Dombret, P. Chevallier, X. Thomas, 2015, American journal of hematology.

P135 Has treatment with EPO+/-G-CSF an impact on progression to AML and survival in low/int-1-risk MDS? A comparison between French-EPO patients and the IMRAW database

H. Dombret, P. Greenberg, P. Fenaux, 2007 .

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group

J. Cayuela, P. Cony-Makhoul, P. Rousselot, 2018, Cancer.

Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study

P. Cony-Makhoul, S. Hayette, P. Rousselot, 2023, British journal of haematology.

Kinetics of early and late molecular recurrences after first-line imatinib cessation in chronic myeloid leukemia: updated results from the STIM2 trial

P. Cony-Makhoul, T. Henni, P. Rousselot, 2022, Haematologica.

Imatinib Optimized Therapy Improves Major Molecular Response Rates in Patients with Chronic Myeloid Leukemia

J. Cayuela, P. Cony-Makhoul, H. Bruzzoni-Giovanelli, 2022, Pharmaceutics.

Hyperhomocysteinemia and high doses of nilotinib favor cardiovascular events in chronic phase Chronic Myelogenous Leukemia patients

J. Drai, E. Blond, F. Mahon, 2016, Haematologica.

Prognostication of Molecular Relapses after Dasatinib or Nilotinib Discontinuation in Chronic Myeloid Leukemia (CML): A FI-LMC STOP 2G-TKI Study Update.

M. Tulliez, G. Guillerm, P. Rousselot, 2019, Blood.

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

P. Cony-Makhoul, E. Deconinck, P. Rousselot, 2019, Blood.

A Multicenter Open Label Phase II Study of Pomalidomide, Cyclophosphamide and Dexamethasone in Relapse Multiple Myeloma Patients Initially Treated with Lenalidomide, Bortezomib and Dexamethasone

M. Mohty, J. Mary, P. Moreau, 2017 .

Bortezomib and High-Dose Melphalan Vs. High-Dose Melphalan As Conditioning Regimen before Autologous Stem Cell Transplantation in De Novo Multiple Myeloma Patients: A Phase 3 Study of the Intergroupe Francophone Du Myelome (IFM 2014-02)

B. Pégourié, P. Moreau, M. Macro, 2017 .

Evaluation of a new rapid D-dimer assay for clinically suspected deep venous thrombosis (Liatest D-dimer).

E. Oger, J. Abgrall, J. Amiral, 1998, American journal of clinical pathology.

A case of chronic myelomonocytic leukaemia and factor XI deficiency with a circulating anticoagulant

J. Abgrall, C. Le Niger, M. Blouch, 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

Pomalidomide and dexamethasone until progression after first salvage therapy in multiple myeloma

P. Moreau, M. Macro, X. Leleu, 2023, British Journal of Haematology.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) In Adults With Philadelphia Chromosome (Ph)-Negative Acute Lymphoblastic Leukemia (ALL): Results From The Group For Research On Adult ALL (GRAALL)

H. Dombret, P. Chevallier, D. Blaise, 2013 .

First-line second generation tyrosine kinase inhibitors in patients with newly diagnosed accelerated phase chronic myeloid leukemia.

P. Cony-Makhoul, I. Tigaud, A. Delmer, 2023, Leukemia research.

Dasatinib plus Peg‐Interferon alpha 2b combination in newly diagnosed chronic phase chronic myeloid leukaemia: Results of a multicenter phase 2 study (DASA‐PegIFN study)

P. Cony-Makhoul, P. Rousselot, F. Mahon, 2022, British journal of haematology.

Interlaboratory Development and Validation of a HRM Method Applied to the Detection of JAK2 Exon 12 Mutations in Polycythemia Vera Patients

V. Ugo, C. Chomienne, S. Tondeur, 2010, PloS one.

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

B. Pégourié, O. Decaux, P. Moreau, 2015, Annals of Hematology.

Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: a retrospective analysis on 112 patients.

A. Stamatoullas, P. Fenaux, N. Vey, 2010, Leukemia research.

Long-term outcome of anemic lower-risk myelodysplastic syndromes without 5q deletion refractory to or relapsing after erythropoiesis-stimulating agents

A. Stamatoullas, P. Fenaux, L. Adès, 2013, Leukemia.

Spontaneous megakaryocytic colony formation does not discriminate between essential thrombocythemia and polycythemia vera

M. Bernard, T. Fest, O. Fardel, 2006, American journal of hematology/oncology.

Fibrinogen Is not an Additional Risk Factor of Thromboembolic Disease in Factor V Leiden Patients

B. Mercier, J. Abgrall, C. Férec, 1999, Thrombosis and Haemostasis.

A Phase 2 study of L‐asparaginase encapsulated in erythrocytes in elderly patients with Philadelphia chromosome negative acute lymphoblastic leukemia: The GRASPALL/GRAALL‐SA2‐2008 study

H. Dombret, S. Leprêtre, P. Chevallier, 2015, American journal of hematology.

Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia.

H. Dombret, S. Chevret, P. Chevallier, 2016, The New England journal of medicine.

[Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia].

J. Cayuela, S. Hayette, O. Nibourel, 2020, Bulletin du cancer.

Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial

M. Vekemans, M. Macro, C. Touzeau, 2024, The Lancet Oncology.